J. Barth

发表

Communication skills training in oncology: a position paper based on a consensus meeting among European experts in 2009.

J. Bensing, L. Fallowfield, F. Stiefel, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study.

M. Stauch, A. Hinke, W. Brugger, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.

M. Stauch, A. Hinke, W. Brugger, 2016, The Lancet. Oncology.

Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial).

A. Hinke, F. Kauff, B. Hertenstein, 2016 .

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas – Final Results of the Randomized Phase III Study NHL 2–2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany)

M. Stauch, A. Hinke, W. Brugger, 2010 .

Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial

R. Greil, H. Hackl, T. Melchardt, 2017, Annals of Hematology.

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

M. Stauch, A. Hinke, W. Brugger, 2013, The Lancet.

Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.

A. Ganser, M. Stauch, W. Brugger, 2017 .

Bendamustin-Rituximab Induction Followed by Observation or Rituximab Maintenance for Newly Diagnosed Patients with Waldenström's Macroglobulinemia: Results From a Prospective, Randomized, Multicenter Study (StiL NHL 7–2008 –MAINTAIN-; ClinicalTrials.gov Identifier: NCT00877214).

R. Greil, U. Jaeger, C. Buske, 2012 .

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy.

I. Bruns, W. Brugger, N. Niederle, 2015, Blood.

Peripheral Blood Stem Cell Mobilization After Bendamustine Containing Chemotherapy in Indolent Lymphomas Is Possible. Results From the Phase III Study of B-R Vs. CHOP-R (NHL 1-2003 trial) of the StiL (Study group indolent Lymphomas, Germany).

W. Brugger, G. Maschmeyer, M. Rummel, 2009 .

JAMA Peer Reviewers in 2019.

Abraham, Christopher C. Baggett, Sarah E. Barlow, 2020, JAMA.

Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial).

R. Greil, A. Ganser, A. Hinke, 2018 .

Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study)

R. Greil, C. Buske, A. Hinke, 2017 .